Ahmedabad-based Zydus Cadila has informed that the company has received an approval from the US Food and Drug Administration (USFDA) to market Risperidone Tablets.

Risperidone is indicated for the acute and maintenance treatment of schizophrenia and the company has got approval to market the drug in the strength of 0.25, 0.5,1,2,3 and 4mg.

Recently, Zydus Cadila has filed an Investigational New Drug application with Drugs Controller General of India for ZYT 1, which is used to prevent heart attack and stroke.

Till date, the group has 41 approvals and has so far filed 79 ANDAs since the commencement of filing process in FY 2003-04.